Earnings Feed
Start Free
REGENERON PHARMACEUTICALS, INC.·4

Feb 28, 4:04 PM ET

SING GEORGE L 4

4 · REGENERON PHARMACEUTICALS, INC. · Filed Feb 28, 2024

Insider Transaction Report

Form 4
Period: 2024-02-26
REGENERON PHARMACEUTICALS, INC.REGN
SING GEORGE L
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2024-02-26$413.33/sh+500$206,665→ 26,849 total
  • Sale

    Common Stock

    2024-02-26$990.00/sh−500$495,000→ 26,349 total
  • Exercise/Conversion

    Common Stock

    2024-02-26$413.33/sh+500$206,665→ 26,849 total
  • Sale

    Common Stock

    2024-02-26$995.00/sh−500$497,500→ 26,349 total
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2024-02-26−1,000→ 5,338 total
    Exercise: $413.33Exp: 2025-01-02→ Common Stock (1,000 underlying)
Holdings

  • Common Stock

    (indirect: By Spouse)
    750

  • Common Stock

    (indirect: By Spouse)
    400

  • Common Stock

    (indirect: By Trust)
    1,000
Footnotes (1)
  • [F1]The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

Documents

1 file
  • 4
    edgardoc.xmlPrimary

    PRIMARY DOCUMENT